Trevena (TRVN) Earns Media Impact Score of 0.07

News articles about Trevena (NASDAQ:TRVN) have trended somewhat positive on Friday, according to Accern. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Trevena earned a news impact score of 0.07 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.4499467496553 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Shares of Trevena (TRVN) remained flat at $$1.73 on Friday. 211,400 shares of the company were exchanged, compared to its average volume of 1,575,175. Trevena has a 52 week low of $1.35 and a 52 week high of $8.00. The stock has a market capitalization of $103.27, a PE ratio of -1.05 and a beta of -0.58. The company has a quick ratio of 4.92, a current ratio of 4.92 and a debt-to-equity ratio of 0.38.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.33) by $0.06. During the same quarter in the previous year, the company earned ($0.57) EPS. equities research analysts forecast that Trevena will post -1.23 EPS for the current year.

A number of research firms have recently issued reports on TRVN. Oppenheimer restated a “buy” rating and set a $5.00 price target on shares of Trevena in a report on Monday, November 13th. HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Trevena in a report on Wednesday, November 8th. Needham & Company LLC cut their price target on shares of Trevena from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, November 8th. Zacks Investment Research downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Finally, Barclays downgraded shares of Trevena from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $15.00 to $2.50 in a research report on Monday, October 16th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $8.09.

WARNING: “Trevena (TRVN) Earns Media Impact Score of 0.07” was reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply